UK-PAS meeting (David Goldfarb from University of British Columbia – PID and micro.)
H5N1 first appeared in 1997 in China but no more cases until early 2000s.
2017 report lots of young children, high mortality (53%). Unrecognised cases never admitted?
New clade 2.3.4.4b in 2021 – crossing over to mammals in Americas. Last year some mild cases related to cows.
Death in Louisiana H5N1 2025 (not the clade in dairy farms), related to poultry (underlying health issues and over 65 years). H5N1 circulating in wild and farmed birds in Scotland, H5N5 back in wild birds.
HPS guidance here.
Case
2024 – 13yr old mild asthma, obesity (117kg), presented with conjunctivitis and fever. Then vomiting and dyspnoea, quickly transferred to PICU. LLL pneumonia. No risk factors.
Biofire resp panel used for PICU – includes pan influenza A antigens, so positive but H1/3 negative. Then did reflexive Xpert assay, which is quantitative. Relatively strong so referred to reference lab.
Genomics done within 4 days. Showed close to “cackling goose” strains. Also identified mutations associated with increased binding (not seen before in H5) so infectivity increased.
At same time Louisana case with same gene type and mutations.
Infection control tricky – new genes! Other studies have suggested incubation up to 13 days. Maintained airborne precautions until 2 negative samples (lower resp samples continued to be positive for 15 days, tracheal just 2 days…)
Note potential exposure to lab staff – discuss!
Ashraf Znait (PICU fellow) – intubated for hypoxia despite BipAP. Echo showed good function on intoropes. Started ECMO at 6 hours after intubation. Double cannulas (IJ and femoral) required to achieve sats of 80%. Dual lumen cannula. Required CRRT for fluid overload and anuria but high pressure with combination so switched to separate femoral dialysis catheter.
SIRS and haemodynamic instability persisted, decided against steroids (higher mortality in influenza cases 2019 – Recovery trial in UK currently?) so plasmapheresis.
D10 off inotropes. D15 before decannulated. D21 extubated.
Mode of acquisition never explained! No immunological problem found.
Ellie MacBain (PID fellow) – case series from 2012 found 75% increased risk of death with delayed oseltamivir treatment. IL6 and IFNgamma, resp sample viral load higher in fatal cases.
Oseltamivir resistance has been described in avian cases of this clade. WHO suggests higher doses (eg 150mg BD), combination therapy, or prolonged treatment.
This case had PCR positive serum with cycle threshold (CT) suggestive of true viraemia. Added amantadine, baloxavir, unable to procure IV zanamavir. From different classes of antiviral in any case.
Never positive bacterial cultures! On/off antibiotics throughout.
Ashley Roberts (Prof PID) – treatment doses used for oseltamivir prophylaxis, for 7-10 days.